• Earlier in June 2026, Stryker voluntarily recalled a single Neptune Smart Docking Station unit in the US after the FDA flagged unverifiable safety testing and a potential electrical shock risk, while a federal court ruled in Stryker’s favor in the OptaBlate patent case and the company advanced new surgical and Mako robotic offerings.
• This mix of tighter quality controls, reduced legal uncertainty, and continued rollout of robotic and surgical technologies could influence how investors assess Stryker’s long-term product reliability and innovation profile.
• We’ll now examine how the favorable OptaBlate court ruling and ongoing Mako expansion shape Stryker’s broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Stryker Investment Narrative Recap

Stryker’s appeal rests on investors believing in its ability to keep expanding its surgical and robotics footprint while managing regulatory, legal, and cost pressures. The single-unit Neptune docking station recall looks limited in scope, while the favorable OptaBlate ruling and Mako rollout help keep the main near term focus on procedure demand and execution, with regulatory and pricing pressures still the biggest overhangs.

The OptaBlate court win is particularly relevant here because it removes a legal dispute around one of Stryker’s technology areas just as it pushes ahead with Mako SmartRobotics and new surgical launches, reinforcing the importance of protecting its innovation engine as a key driver of future procedure volumes and equipment placements.

But against that backdrop, investors should still be aware of how prolonged EU MDR approvals could...

Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029.

Uncover how Stryker's forecasts yield a $386.80 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community currently see Stryker’s fair value between US$340.49 and US$386.80, reflecting a wide spread of individual expectations. You can weigh those views against the dependence on sustained procedure growth and robotics adoption, which could have a meaningful effect on how the company’s performance ultimately lines up with these estimates.

Explore 6 other fair value estimates on Stryker - why the stock might be worth as much as 26% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Stryker research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

No Opportunity In Stryker?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.